Table.
Baseline demographics and characteristics by study group in the analysis population of the general cohort
|
4-week interval study groups |
12-week interval study groups |
Overall (n=664) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| ChAd–ChAd (n=83) | ChAd–BNT (n=83) | BNT–BNT (n=84) | BNT–ChAd (n=83) | ChAd–ChAd (n=89) | ChAd–BNT (n=77) | BNT–BNT (n=87) | BNT–ChAd (n=78) | ||
| Age, years | |||||||||
| Mean | 58·4 (4·8) | 58·3 (4·8) | 58·3 (5·0) | 57·5 (4·6) | 57·6 (5·1) | 58·8 (4·4) | 58·2 (4·6) | 58·2 (4·4) | 58·2 (4·7) |
| Median | 57·6 (54·3–62·4) | 58·1 (54·1–62·4) | 57·6 (54·2–62·4) | 56·7 (53·8–60·5) | 57·7 (53·1–61·2) | 58·5 (55·5–61·0) | 57·2 (54·9–61·8) | 58·4 (54·6–60·6) | 57·7 (54·3–61·6) |
| Aged 50–59 years | 50 (60%) | 50 (60%) | 55 (65%) | 61 (73%) | 63 (71%) | 49 (64%) | 55 (63%) | 50 (64%) | 433 (65%) |
| Aged ≥60 years | 33 (40%) | 33 (40%) | 29 (35%) | 22 (27%) | 26 (29%) | 28 (36%) | 32 (37%) | 28 (36%) | 231 (35%) |
| Gender | |||||||||
| Men | 49 (59%) | 47 (57%) | 42 (50%) | 45 (54%) | 47 (53%) | 44 (57%) | 47 (54%) | 49 (63%) | 370 (56%) |
| Women | 34 (41%) | 36 (43%) | 42 (50%) | 38 (46%) | 42 (47%) | 33 (43%) | 40 (46%) | 29 (37%) | 294 (44%) |
| Ethnicity | |||||||||
| White | 66 (80%) | 62 (75%) | 68 (81%) | 60 (72%) | 68 (76%) | 60 (78%) | 67 (77%) | 62 (79%) | 513 (77%) |
| Black | 1 (1%) | 1 (1%) | 0 | 2 (2%) | 3 (3%) | 1 (1%) | 2 (2%) | 1 (1%) | 11 (2%) |
| Asian | 12 (14%) | 13 (16%) | 6 (7%) | 9 (11%) | 8 (9%) | 10 (13%) | 9 (10%) | 9 (12%) | 76 (11%) |
| Mixed | 4 (5%) | 5 (6%) | 8 (10%) | 9 (11%) | 7 (8%) | 5 (6%) | 6 (7%) | 4 (5%) | 48 (7%) |
| Other | 0 | 2 (2%) | 2 (2%) | 3 (4%) | 3 (3%) | 1 (1%) | 3 (3%) | 2 (3%) | 16 (2%) |
| Comorbidities | |||||||||
| Cardiovascular | 19 (23%) | 16 (19%) | 16 (19%) | 20 (24%) | 17 (19%) | 21 (27%) | 16 (18%) | 18 (23%) | 143 (22%) |
| Respiratory | 13 (16%) | 10 (12%) | 9 (11%) | 11 (13%) | 7 (8%) | 8 (10%) | 12 (14%) | 9 (12%) | 79 (12%) |
| Diabetes | 7 (8%) | 8 (10%) | 0 | 2 (2%) | 2 (2%) | 1 (1%) | 1 (1%) | 4 (5%) | 25 (4%) |
| Timing of 6-month visit, days* | |||||||||
| Mean | 153 (5) | 154 (7) | 153 (6) | 154 (5) | 176 (19) | 178 (19) | 177 (15) | 176 (17) | 164 (17) |
| Median | 154 (139–171) | 154 (142–198) | 154 (120–174) | 154 (141–168) | 180 (138–225) | 179 (141–239) | 181 (140–208) | 176 (138–223) | 154 (120–239) |
Data are n (%), mean (SD), or median (IQR).
*
Days since second dose.